Nelly Briand

Summary

Affiliation: Inserm
Location: Paris,

Publications

  1. ncbi Perinatal zidovudine prophylaxis in HIV type-1-infected pregnant women with thalassaemia carriage in Thailand
    Nelly Briand
    Institut National d Etudes Demographiques, Paris, France
    Antivir Ther 14:117-22. 2009
  2. ncbi No relation between in-utero exposure to HAART and intrauterine growth retardation
    Nelly Briand
    INSERM, U822, Le Kremlin Bicetre, France
    AIDS 23:1235-43. 2009
  3. ncbi Risk of extended viral resistance in human immunodeficiency virus-1-infected Mozambican children after first-line treatment failure
    Paula Vaz
    Pediatric Day Hospital at Maputo Central Hospital, Maputo, Mozambique
    Pediatr Infect Dis J 28:e283-7. 2009
  4. ncbi Long-term outcomes in adolescents perinatally infected with HIV-1 and followed up since birth in the French perinatal cohort (EPF/ANRS CO10)
    C Dollfus
    Assistance Publique Hopitaux de Paris AP HP, Service d hématologie et d oncologie pédiatrique, Hopital d Enfants Armand Trousseau, Le Kremlin Bicetre, France
    Clin Infect Dis 51:214-24. 2010
  5. ncbi Growth of human immunodeficiency virus-uninfected children exposed to perinatal zidovudine for the prevention of mother-to-child human immunodeficiency virus transmission
    Nelly Briand
    , Paris, France
    Pediatr Infect Dis J 25:325-32. 2006
  6. ncbi Lopinavir/ritonavir-based antiretroviral therapy in human immunodeficiency virus type 1-infected naive children: rare protease inhibitor resistance mutations but high lamivudine/emtricitabine resistance at the time of virologic failure
    Pierre Frange
    Unite d immunologie, Hématologie et Rhumatologie pédiatriques, Assistance Publique Hopitaux de Paris, Hopital Necker, Paris, France
    Pediatr Infect Dis J 30:684-8. 2011
  7. ncbi Hematological safety of perinatal exposure to zidovudine in uninfected infants born to HIV type 1-infected women in Thailand
    Nelly Briand
    Institut National d Etudes Démographiques INED, Paris, France
    AIDS Res Hum Retroviruses 26:1163-6. 2010
  8. ncbi Previous antiretroviral therapy for prevention of mother-to-child transmission of HIV does not hamper the initial response to PI-based multitherapy during subsequent pregnancy
    Nelly Briand
    CESP INSERM U1018, Equipe VIH et IST Le Kremlin Bicêtre, France
    J Acquir Immune Defic Syndr 57:126-35. 2011

Detail Information

Publications8

  1. ncbi Perinatal zidovudine prophylaxis in HIV type-1-infected pregnant women with thalassaemia carriage in Thailand
    Nelly Briand
    Institut National d Etudes Demographiques, Paris, France
    Antivir Ther 14:117-22. 2009
    ....
  2. ncbi No relation between in-utero exposure to HAART and intrauterine growth retardation
    Nelly Briand
    INSERM, U822, Le Kremlin Bicetre, France
    AIDS 23:1235-43. 2009
    ..The use of HAART during pregnancy is now standard care to prevent mother-to-child HIV transmission in developed countries. There is controversy about its impact on low birth weight...
  3. ncbi Risk of extended viral resistance in human immunodeficiency virus-1-infected Mozambican children after first-line treatment failure
    Paula Vaz
    Pediatric Day Hospital at Maputo Central Hospital, Maputo, Mozambique
    Pediatr Infect Dis J 28:e283-7. 2009
    ..The incidence and profile of resistance in children receiving World Health Organization-recommended treatment remains to be evaluated on a large scale...
  4. ncbi Long-term outcomes in adolescents perinatally infected with HIV-1 and followed up since birth in the French perinatal cohort (EPF/ANRS CO10)
    C Dollfus
    Assistance Publique Hopitaux de Paris AP HP, Service d hématologie et d oncologie pédiatrique, Hopital d Enfants Armand Trousseau, Le Kremlin Bicetre, France
    Clin Infect Dis 51:214-24. 2010
    ..Given the limited therapeutic options available during the early years of these patients' lives and the challenge presented by treatment adherence during adolescence, the long-term outcomes among this population are encouraging...
  5. ncbi Growth of human immunodeficiency virus-uninfected children exposed to perinatal zidovudine for the prevention of mother-to-child human immunodeficiency virus transmission
    Nelly Briand
    , Paris, France
    Pediatr Infect Dis J 25:325-32. 2006
    ..Neither the total nor the postnatal duration of exposure was associated with changes in infant Z-scores from 6 weeks to 18 months of age...
  6. ncbi Lopinavir/ritonavir-based antiretroviral therapy in human immunodeficiency virus type 1-infected naive children: rare protease inhibitor resistance mutations but high lamivudine/emtricitabine resistance at the time of virologic failure
    Pierre Frange
    Unite d immunologie, Hématologie et Rhumatologie pédiatriques, Assistance Publique Hopitaux de Paris, Hopital Necker, Paris, France
    Pediatr Infect Dis J 30:684-8. 2011
    ..Lopinavir/ritonavir (LPV/r) is now the protease inhibitor regimen of choice in the first-line antiretroviral therapy for children <6 years of age...
  7. ncbi Hematological safety of perinatal exposure to zidovudine in uninfected infants born to HIV type 1-infected women in Thailand
    Nelly Briand
    Institut National d Etudes Démographiques INED, Paris, France
    AIDS Res Hum Retroviruses 26:1163-6. 2010
    ..Despite the differences in hemoglobin levels, grade 3 or 4 anemia did not significantly differ by maternal or infant zidovudine duration. The clinical impact appeared modest, but longer exposure may warrant close monitoring...
  8. ncbi Previous antiretroviral therapy for prevention of mother-to-child transmission of HIV does not hamper the initial response to PI-based multitherapy during subsequent pregnancy
    Nelly Briand
    CESP INSERM U1018, Equipe VIH et IST Le Kremlin Bicêtre, France
    J Acquir Immune Defic Syndr 57:126-35. 2011
    ..Few data are available on the possible long-term negative effects of a short exposure to antiretroviral therapy (ART) for prevention of mother-to-child transmission (PMTCT)...